Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.

Ibrutinib is a first-in-class oral covalent inhibitor of Bruton's tyrosine kinase that has demonstrated clinical benefit for many patients with B cell malignancies. Positive results in initial trials led the U.S.